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Identification of regulatory 
variants associated with genetic 
susceptibility to meningococcal 
disease
Lisa Borghini1,2, Eileen Png  2, Alexander Binder3, Victoria J. Wright  4, Ellie pinnock5, 
Ronald de Groot6, Jan Hazelzet7, Marieke Emonts8,9, Michiel Van der Flier6, 
Luregn J. Schlapbach  10,11,12,13, Suzanne Anderson14, Fatou Secka14, Antonio Salas  15, 
Colin Fink5, Enitan D. Carrol16, Andrew J. Pollard17, Lachlan J. Coin18, Taco W. Kuijpers19, 
Federico Martinon-Torres  20,21, Werner Zenz3, Michael Levin4, Martin L. Hibberd2,22, 
Sonia Davila1,23,24 & EUCLIDS consortium
Non-coding genetic variants play an important role in driving susceptibility to complex diseases but 
their characterization remains challenging. Here, we employed a novel approach to interrogate the 
genetic risk of such polymorphisms in a more systematic way by targeting specific regulatory regions 
relevant for the phenotype studied. We applied this method to meningococcal disease susceptibility, 
using the DNA binding pattern of RELA – a NF-kB subunit, master regulator of the response to infection 
– under bacterial stimuli in nasopharyngeal epithelial cells. We designed a custom panel to cover 
these RELA binding sites and used it for targeted sequencing in cases and controls. Variant calling and 
association analysis were performed followed by validation of candidate polymorphisms by genotyping 
in three independent cohorts. We identified two new polymorphisms, rs4823231 and rs11913168, 
showing signs of association with meningococcal disease susceptibility. In addition, using our genomic 
data as well as publicly available resources, we found evidences for these SNPs to have potential 
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regulatory effects on ATXN10 and LIF genes respectively. The variants and related candidate genes 
are relevant for infectious diseases and may have important contribution for meningococcal disease 
pathology. Finally, we described a novel genetic association approach that could be applied to other 
phenotypes.
A vast majority of Single Nucleotide Polymorphism (SNP) associated with susceptibility to complex diseases 
identified through Genome Wide Association Studies (GWAS) are located in non-coding regions of the genome1. 
They have been hypothesized to affect gene regulation, notably via variation in transcription factor bind-
ing2,3. Despite the growing interest and resources available to study these polymorphisms, understanding their 
functional effect remains challenging for several reasons: (i) most associated SNPs are still identified through 
genome-wide genotyping arrays, which does not allow for all variants to be investigated but only tag SNPs linking 
a locus to a change in gene expression, (ii) studying the right cell type in the right environment is necessary to 
uncover the mechanism of action of a variant because gene expression and transcription factor binding varies 
across tissues and conditions4. In an attempt to address these challenges, we employed a reverse genetic approach 
to identify regulatory variants involved in the innate immune response.
We have recently identified genome-wide binding of RELA, one of the Nuclear Factor kappa B (NF-kB) mem-
bers involved in the response to microbes, as well as gene expression data following microbial stimuli in naso-
pharyngeal epithelial cells5. In addition we also investigated epigenetic changes following a potent gram negative 
bacterial endotoxin, Lipopolysaccharide (LPS), in the same cells6.
We concluded that some of the potential regulatory regions identified in our previous study will be relevant in 
mounting an immune response against infectious pathogens with the following characteristics: (i) airborne trans-
mitted, (ii) able to infect human epithelial cells, (iii) able to bind some of the receptors targeted in our previous 
study, and lastly (iv) shown to have a host-genetic susceptibility component. As such we identified Meningococcal 
Disease (MD) as a relevant example, complying with all the requirements mentioned above.
MD is a severe infection resulting in potentially lethal meningitis and sepsis. It is caused by a gram negative 
bacterium, Neisseria meningitides, which is transmitted through respiratory secretions. The bacterium colonizes 
the nasopharynx before crossing the epithelium to cause the serious invasive disease7. Interestingly, asymptomatic 
carriage in the nasopharyngeal mucosae is relatively common with the bacteria being detected in about 10% of 
the population8.
Neisseria meningitides has been shown to bind several pattern recognition receptors, TLR2, TLR4, TLR9 and 
NOD receptors9,10, leading to the activation of downstream signaling pathways. One of the main TF activated is 
the master regulator of the innate immune system, NF-kB11.
Previous studies have demonstrated that host genetic make-up is a risk factor for MD12 and a number of pol-
ymorphisms have been associated with susceptibility to the disease, notably in innate immunity genes13. Thus, 
host-pathogen interactions are decisive in the development of the disease, notably at the nasopharynx epithelium 
where epithelial cells are critical in detecting pathogens and organizing an efficient immune response14.
Finally, our group has been involved in previous genome wide association studies (GWAS) for MD suscepti-
bility15,16, therefore we have access to well-characterized cohorts for this disease.
Briefly, our approach consisted of identifying regulatory regions in response to bacterial stimulation of phar-
yngeal epithelial cells which were then used to perform targeted sequencing in cohorts of healthy individuals 
and MD patients followed by further validation in three European cohorts. This strategy allowed us to identify 
two novel SNPs, rs4823231 (P-value = 9.58 × 10−5, OR = 0.73) and rs11913168 (P-value = 3.46 × 10−3, OR = 0.77) 
showing association with genetic susceptibility to MD.
Results
Selection of regulatory regions relevant for airborne bacterial infection. We have previously iden-
tified RELA genome-wide binding sites as well as gene expression in Detroit 562 cells in response to different 
microbial stimuli5 and in FaDu cells under LPS stimulation. Both of these lines are pharyngeal epithelial cells. In 
addition, we have identified H3K27ac changes following LPS stimulus in both cell lines6. The regions detected 
were particularly relevant for infectious respiratory diseases, especially bacterial infection, and were selected for 
targeted sequencing (further details on region selection can be found in Methods).
In total, 9,551 genomic regions were selected, covering 9,943,597 basepairs (bp) (see Supplementary Fig. S1A 
for an example of the regions covered). Expectedly, Gene Ontology analysis on the nearby genes revealed that 
these regions were highly enriched for the “immune response” as well as “response to other organism”, which 
demonstrates biological relevance to infection (Supplementary Fig. S1B).
Using the Nimblegen technology, these regions were used to design a custom probes set as baits to specifically 
capture targeted fragments for sequencing. The capture designed consisted of 16,784 probes (Supplementary 
Table S1) resulting in 8,923,013 bp of the initial targets submitted covered (89.7%) and an estimated 9,569,494 bp 
covered by targeted sequencing (96.2%). Only 37 of the regions submitted could not be included (mainly due to 
sequence repeat) and showed no coverage in the probes designed (Supplementary Table S2).
Targeted sequencing in meningococcal disease cases and controls. First, we performed targeted 
sequencing of the selected regions in 238 MD cases and 237 controls from Western Europe. Several hybridiza-
tion reactions were tested for enrichment by qPCR and showed satisfactory results (Supplementary Fig. S2A). 
Moreover, the sequencing reads were also highly specific for the regions covered in the capture (Supplementary 
Fig. S2B). This indicates that the targeted sequencing experiments were successful. Depth of coverage was 
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satisfying across all samples (Supplementary Fig. S2C) with an average of 61.8x and the majority of the capture 
regions (16,357 out of 16,784) were characterized with sufficient coverage and adequate mapping.
Variant calling was performed using GATK Unified Genotyper, following the best practices17 and identi-
fied 92,929 Single Nucleotide Polymorphisms (SNP). Stringent filtering steps were then applied (more details in 
Methods) and finally 30,542 SNPs remained for the association analysis (Supplementary Fig. S3A). Samples were 
also filtered (Supplementary Fig. S3B,C), removing the samples with first degree relatives (N = 10), PCA outliers 
(N = 5) and samples with insufficient call rates (<95%, N = 0). Ultimately, 460 samples remained to be considered 
for the association study (235 cases and 225 controls).
Genetic association analysis was performed using a logistic regression model and adjusting for population 
heterogeneity by correcting the P-value with the genomic inflation factor (GC = 1.049). The top 15 SNPs showing 
the most significant association are reported in Table 1 (see Supplementary Table S3 for the full list).
Validation of top SNPs and Meta-analysis. Selected SNPs from the discovery phase were genotyped 
either by mass array with the Sequenom technology or by GWAS array using the previously generated data15. 
They were typed in 3 validation cohorts from Western Europe, Spain and the UK.
Using the same stringent criteria as the discovery stage, quality control filtering was done on the SNPs as well 
as the samples. Independent association analysis was performed separately in the three validation cohorts using 
the same method as in the discovery cohort. A meta-analysis including all four cohorts was then computed (see 
Supplementary Tables S4 and S5 for the association results from the Sequenom and GWAS array genotyping 
respectively).
The top SNPs validated with a meta-analysis P-value < 0.05 are reported in Table 2. We then focused on the 
top two SNPs – rs4823231 and rs11913168 – in the rest of the study as they showed much lower P-values.
We identified the most significant association in the meta-analysis for rs4823231, the P-value for association 
was 9.6 × 10−5. This variant showed a strong protective effect of the minor allele (T) in the discovery cohort with 
an odds ratio (OR) of 0.56 and P-value of 1.12 × 10−3. Although the associations in each validation cohorts did 
not reach significance, they all showed a similar trend with comparable P-values, frequencies as well as ORs 
(Table 2). The associations of the risk allele (T) across stages were in the same protective direction captured with 
the meta-analysis OR of 0.73 (Table 2).
The SNP rs4823231 is located in an intron of the ATXN10 gene on chromosome 22. In order to interrogate 
potential regulatory effects of this SNP, we looked for it in the HaploReg data base. The region where the SNP is 
located was identified as an enhancer in 14 tissues based on histone marks data from the Roadmap Epigenetic18. 
Our ChIP-seq for H3K27ac in two pharyngeal epithelial cell lines also revealed high deposition of this mark at 
the SNP location (Fig. 1A). This suggest that this region is active in this relevant cell type. Moreover, we noticed 
that the SNP is located very near a RELA binding site induced by microbial stimulation in these same cell lines 
(Fig. 1A).
Our panel was designed to include RELA binding sites located near a differentially expressed gene or a region 
of LPS-induced H3K27ac changes. In this case, the FBLN1 gene located about 100 Kb upstream of rs4823231 was 
found to be up-regulated in one RNA-seq experiment after M tri-DAP stimulation of Detroit 562 cells and LPS 
stimulation of FaDu cells (Supplementary Fig. S4A). However, the duplicate RNA-seq experiment performed later 
on and RT-qPCR on these conditions did not replicate this change in expression (Supplementary Fig. S4B). In 
fact, results for this SNP from HaploReg revealed that rs4823231 is an eQTL associated with the expression of the 
ATXN10 gene in many tissues (based on GTEx data). This association was particularly significant in the oesoph-
agus mucosae tissue (P-value = 2.6 × 10−18), which is the closest tissue to our model (Supplementary Table S6). A 
closer look at the GTEx data19 from which this results were extracted, we observed that individuals carrying the 
SNP Chr Location
Risk 
allele
Freq in 
cases
Freq in 
control P-value
Odds 
ratio
OR – 
95% CI OR + 95% CI
rs12476782 2 191472880 A 0.26 0.16 2.38 × 10−4 1.9 1.4 2.6
rs11625840 14 22627848 A 0.38 0.26 2.66 × 10−4 1.7 1.3 2.3
rs2242543 14 22694331 A 0.36 0.25 3.77 × 10−4 1.7 1.3 2.4
rs79840975 18 56209387 T 0.02 0.08 4.06 × 10−4 0.3 0.1 0.5
rs11585994 1 8258226 C 0.16 0.26 4.18 × 10−4 0.5 0.4 0.8
rs988997 14 22693832 G 0.36 0.25 4.57 × 10−4 1.7 1.3 2.3
rs10488042 7 101652458 A 0.19 0.11 4.87 × 10−4 2.1 1.4 3.1
rs7130129 11 65354926 A 0.42 0.54 5.27 × 10−4 0.6 0.5 0.8
rs2240985 2 37899654 A 0.08 0.16 8.07 × 10−4 0.5 0.3 0.7
rs11228991 11 57078876 G 0.12 0.06 8.76 × 10−4 2.4 1.4 3.9
rs12717364 14 22693912 C 0.50 0.38 9.86 × 10−4 1.6 1.2 2.0
rs13379037 14 22693679 C 0.50 0.38 1.03 × 10−3 1.6 1.2 2.0
rs2595370 18 29239527 A 0.09 0.16 1.09 × 10−3 0.5 0.3 0.7
rs2468842 11 18154120 A 0.16 0.26 1.12 × 10−3 0.6 0.4 0.8
rs4823231 22 46088119 T 0.16 0.25 1.12 × 10−3 0.6 0.4 0.8
Table 1. Association analysis results for the top 15 SNPs in the discovery cohort. Chr: chromosome, Freq: 
Frequency, OR: Odds Ratio, CI: Confidence Interval.
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genotype T/T have a higher level of ATXN10 expressed in their oesophagus mucosae compared to those with the 
genotype A/A (Supplementary Fig. S4C). When we looked at the expression of ATXN10 in our data, we found 
that this gene was highly expressed in both Detroit 562 and FaDu cells (average FPKM~325 in both cell lines in 
RNA-seq experiments and easily detectable by RT-qPCR – Supplementary Fig. S4D) but there was no change 
in expression after microbial stimulation. A further inspection of the Human Protein Atlas20 revealed protein 
expression in most tissues available in this database (Supplementary Fig. S4E).
As rs4823231 is not located inside a RELA binding sites identified in our study, it is less likely to have an 
effect on RELA binding itself. However, it is located very near and could therefore influence binding of a RELA 
co-factor. HaploReg returned this SNP to potentially alter 4 transcription factor motifs, DMRT4, DMRT7, E2F and 
FOXA. In addition, RegulomeDB tool also indicated rs4823231 to disrupt two factors motifs, DMRT4 and IRX3 
(Supplementary Fig. S5). Concerning the DMRT4 motif, the SNP is located at a position that is less conserved where 
any of the A, T or C bases can be found thus it is less likely to have an effect on this factor binding. This is further 
captured by the score given to the reference and alternate alleles in HaploReg which is very similar. The same obser-
vation is true for DMRT7 motifs where the variant occurs at a variable base position. However, IRX3 motif alteration 
reported by regulomeDB is interesting as rs4823231 is located at a position where a base C or T is present, suggesting 
that the major allele A would disrupt the motif (Fig. 1B). Moreover, the E2F and FOXA motifs match identified 
in HaploReg are also of interest as they showed that the major allele A (base T highlighted in Fig. 1B as the motif 
matches the reverse complement strand) could create a motif for these factors to bind that location.
The second top SNP more significantly associated with MD susceptibility in our study was rs11913168. This 
variant showed association with a P-value of 8.69 × 10−3 in the Western Europe discovery cohort which was 
replicated in the British validation cohort with a P-value of 3.7 × 10−2. The Spanish cohort showed a weak asso-
ciation (P-value = 0.53) while the Western European cohort revealed sign of association but not very strong 
(P-value = 0.21). Nonetheless, all cohorts showed a similar trend leading to a meta-analysis P-value of 3.5 × 10−3 
and an OR of 0.77 suggesting a protective effect of the minor allele A.
The SNP rs11913168 is located in an intergenic region on chromosome 22 (Fig. 2). According to HaploReg, 
this SNP is under sequence constraint (by GERP and SiPhy methods) and this is also observed in the UCSC 
genome browser with positive PhyloP score at this particular location (Supplementary Fig. S6). HaploReg 
reported that the SNP is located in a region with enhancer mark in 14 cell types, DNase sites in 29 tissues and 
10 bound proteins which could be seen in the UCSC genome browser (Supplementary Fig. S6). In our genomic 
data, we also found that this SNP was located in a region with H3K27ac marks in both Detroit 562 and FaDu cells 
(Fig. 2A). Notably, in FaDu cells, this region exhibited increased H3K27ac signal after LPS stimulation as well 
as a bigger region without acetylation signal (Fig. 2B). This can be linked to nucleosome remodeling leading to 
a larger nucleosome-depleted region and transcription factor binding, characteristic of an active enhancer21. In 
addition, rs11913168 was located within a RELA binding site in both cell lines.
The SNP rs11913168 is situated between two genes, HORMAD2 and LIF (Fig. 2). Interestingly, LIF was found 
to be up-regulated following stimulation of Detroit 562 cells with microbial stimuli as well as stimulation of FaDu 
cells with LPS (Fig. 3A). This was further validated experimentally in FaDu cells after LPS treatment (Fig. 3B). 
Moreover, using publicly available Hi-C data from Jin et al.22 we found evidences of chromatin interaction 
SNP rs4823231 rs11913168 rs72710816 rs79840975 rs17428132 rs1877782
Chromosome 22 22 5 18 6 15
location (base pair) 46088119 30606564 97562 56209387 32687119 90703836
risk allele T A C T T A
Validation method Sequenom GWAS array Sequenom Sequenom Sequenom Sequenom
Meta-analysis
P-value 9.58 × 10−5 3.46 × 10−3 0.014 0.031 0.032 0.047
Odds ratio 0.7 0.8 1.3 0.6 0.8 0.8
Discovery – 
Western Europe
P-value 1.12 × 10−3 8.69 × 10−3 2.99 × 10−3 4.06 × 10−4 2.52 × 10−3 1.40 × 10−3
Frequency in cases 0.16 0.07 0.14 0.02 0.34 0.20
Frequency in controls 0.25 0.13 0.08 0.08 0.46 0.29
Odds ratio 0.6 0.5 2.0 0.3 0.7 0.6
Validation – 
Western Europe
P-value 0.10 0.21 0.56 0.20 0.49 0.48
Frequency in cases 0.13 0.10 0.11 0.04 0.41 0.25
Frequency in controls 0.17 0.12 0.10 0.06 0.47 0.27
Odds ratio 0.7 0.8 1.1 0.7 0.8 0.9
Validation - Spain
P-value 0.18 0.53 0.24 0.93 0.75 1.00
Frequency in cases 0.14 0.09 0.14 0.03 0.40 0.23
Frequency in controls 0.16 0.10 0.12 0.03 0.40 0.23
Odds ratio 0.8 0.9 1.2 1.0 1.0 1.0
Validation - UK
P-value 0.12 0.037 0.25 0.12 0.68 0.030
Frequency in cases 0.15 0.09 0.13 0.03 0.37 0.23
Frequency in controls 0.19 0.11 0.11 0.05 0.38 0.29
Odds ratio 0.8 0.8 1.3 0.6 0.9 0.7
Table 2. Association results for the top validated SNPs.
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between the region containing rs11913168 and regions around the LIF gene (Supplementary Fig. S7A). Taking 
into consideration these data, we hypothesized that the region where the SNP is located is an enhancer of LIF 
and that chromatin looping would bring this regulatory region and the gene close to each other. We searched 
available resources listing known NF-kB targets (see Methods) but we could not find LIF on any of these lists. 
Thus we investigated it in our system. We pre-treated the FaDu cells with a widely used NF-kB inhibitor, BAY 
11–7082, before LPS stimulation to inhibit RELA. Indeed, we observed that this pre-treatment abolished RELA 
activation (Supplementary Fig. S7B) as well as up-regulation of known NF-kB target genes TNF and NFKBIA 
(Supplementary Fig. S7C) following treatment. In the same conditions, LIF up-regulation following LPS stimula-
tion was also completely suppressed (Fig. 3B), suggesting that this gene is regulated by NF-kB. Therefore, binding 
of RELA at the regulatory region where rs11913168 is located could be potentially regulating LIF expression.
Based on our ChIP-seq data, we noticed that the Detroit 562 cells that we used for our genomic analyses were 
heterozygous (G/A) for rs11913168 and this was further validated by Sanger sequencing (Supplementary Fig. S8A). 
We investigated any allelic bias for one allele or the other in our RELA and H3K27ac data. By counting the reads car-
rying the G or A allele, we noticed that there were more reads covering the G allele. After ensuring that there was no 
strand bias (Supplementary Fig. S8B), we tested this statistically and found that the G allele was indeed significantly 
enriched in the RELA ChIP-seq (P-value = 2.8 × 10−13) and H3K27ac ChIP-seq in control (P-value = 2.9 × 10−3) and 
LPS (P-value = 0.018) conditions (Table 3). This suggests an allelic bias where the transcription binds preferentially 
to the base G at that position than to the base A and this histone mark follows the same trend. The same analysis on 
input DNA also revealed more reads containing the base G compared to A, although this did not reach statistical 
significance probably due to the very small number of reads detected in this data-set.
Figure 1. Genomic data for rs4823231 and motif disruption. (A) UCSC genome browser view of the RELA 
and H3K27ac ChIP-seq data generated in two nasopharyngeal epithelial cell lines. (B) Potential disruption of 
transcription factor motifs induced by rs4823231. The SNP position is indicated by the red boxes. Ref: reference, 
Alt: alternate.
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Discussion
In this study, we used genomic data generated in nasopharyngeal epithelial cells stimulated with microbial 
components, modelling airborne bacterial infection, to design a capture probes panel for targeted sequencing. 
Association analysis and further validation by genotyping in three independent cohorts revealed two new SNPs 
associated with MD susceptibility in European populations: rs4823231 and rs11913168. Although these two SNPs 
showed some evidence of association, the P-value from the meta-analysis would not withstand adjustment for 
multiple testing if applied.
The SNP with the smallest P-value in this study was rs4823231 (P-value = 9.6 × 10−5), showing a protective 
effect of the minor allele (T) (OR = 0.73). The risk effects of this variant across the different cohorts was variable, 
especially between the discovery and validation cohorts. It likely to be due to the variation in allele frequencies 
in controls in the discovery cohort against the three validation cohorts. Yet, these percentages remained coherent 
and in line with the known frequencies in European populations reported in public data bases. Indeed, dbSNP 
data base reported the following frequencies in the European population: 82.5% A and 17.5% T in the HapMap 
data and 83.4% A and 16.6% T in the 1000 Genome project data. Moreover, all three validation cohorts showed 
the same trend with the minor allele T being less common in controls than in cases, with similar effect sizes and 
P-values. The limited sample size of these cohorts could explain why the P-values did not reach a more significant 
level. This is especially true for the Spanish and the British cohorts as they contained a small number of cases and 
controls respectively. The data base dbSNP also revealed differences in terms of allele frequencies across popu-
lations. Indeed, Africans were much less likely to carry the T allele, with HapMap and the 1000 Genome Project 
data reporting frequencies of 0.8% and 1.8% respectively. Our analysis showed that the T allele has a protective 
effect, thus the fact that this allele is uncommon in this population may contribute to the epidemic scale of menin-
gococcal disease in Africa7.
One of the candidate gene on which rs4823231 could have an effect is ATXN10 as it was reported by the GTEx 
consortium19 that this genetic variant is an eQTL for this gene. The ATXN10 gene was first described in neurons 
where it is highly expressed and involved in growth and apoptosis23. However, this gene has been later shown to 
be expressed in many tissues, as supported by our search on the Human Protein Atlas. Recently, research on HeLa 
cells showed that decreased expression of ATXN10 leaded to defect in cytokinesis24, thus further supporting its 
role in the cell cycle in various cell types. There is preliminary evidence suggesting a link between ATXN10 and 
the NF-kB pathway. Warner et al. conducted an RNAi screen in HEK cells to identify genes involved in the NF-kB 
response to NOD2 stimulation, an intracellular PRR targeted by certain motifs of bacterial peptidoglycan. They 
reported that knock-down of ATXN10 leaded to a reduced NF-kB activity measured by a decrease in reporter 
expression following stimulation of NOD225. Moreover, they further showed that the same knock-down led to 
Figure 2. Genomic data for rs11913168. RELA and H3K27ac ChIP-seq data following LPS stimulation of 
Detroit 562 and FaDu cells are represented. The SNP of interest is indicated with a black line. The lower panel 
(B) consists of a magnification of the dashed box in the upper panel (A).
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a reduced IL-8 production following stimulation26. The NF-kB pathway plays an important role in survival and 
apoptosis11, thus this could explain how ATXN10 is also involved in these processes. Overall, these evidences 
suggest that high level of expression of this gene is beneficial for cell division and survival, especially following 
microbial detection. This is in line with the eQTL effect seen for rs4823231 and our association results. Indeed, 
the T allele for this SNP was associated with a higher level of ATXN10 and this allele also showed a protective 
effect in our analysis with the healthy controls being more likely to carry this allele than the MD patients (see 
Supplementary Fig. S9 for a schematic). These changes in expression could have critical consequences on tissue 
integrity due to the role of ATXN10 and could in turn influence bacterial infection outcome. However, the mech-
anism by which rs4823231 leads to changes in ATXN10 expression remains elusive. We can hypothesize that it 
could be due to variation in TF binding at this location as we found that the SNP potentially impacted motifs for 
IRX3, E2F and FOXA. The possible effect on E2F binding is of particular interest as these factors are involved 
in the cell cycle and apoptosis. Moreover, some members of the E2F family are repressors27 which could explain 
that recruitment at this locus via the binding motif created by the major allele A would result in repression of 
ATXN10 expression. In addition one of the E2F member, E2F1, has been shown to interact with RELA following 
LPS stimulation28.
The second most significant SNP, rs11913168 (P-value = 3.46 × 10−3), revealed a protective effect of the A 
allele compared to the more common G allele with an odds ratio of 0.77. The British and Western European vali-
dations cohorts were in line with the discovery cohort, especially the British cohort for which a strong association 
Figure 3. LIF expression and NF-kB regulation. (A) The bar graph consists of the average log2FC between two 
RNA-seq experiments following 4 stimuli in Detroit 562 cells (green – see legend) or LPS stimulation in FaDu 
cells (orange) compared to the control condition without any treatment. (B) LIF expression following LPS 
stimulation in FaDu cells without (DMSO) or with pre-treatment with BAY 11–7082 (BAY inhibitor) compared 
to the control condition without treatment. Each dot represent the results from one experiment and the black 
dash is the mean between duplicates. Significance was tested with a 2-sample T-test for which the P-value is 
reported.
Data-set
Number of reads P-value (binomial test 
for allelic bias)Allele G Allele A Total
RELA ChIP-seq 265 (68%) 123 (32%) 388 2.8 × 10−13
Control H3K27ac ChIP-seq 63 (65%) 33 (34%) 97 2.9 × 10−3
LPS H3K27ac ChIP-seq 60 (62.5%) 36 (37.5%) 96 1.8 × 10−2
Table 3. Strand bias for rs11913168 in our RELA and H3K27ac ChIP-seq data.
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was reported. The Western European validation cohort showed a similar effect size although it did not reach the 
same level of significance, probably due to the limited number of cases available in this population. However, the 
effect of the SNP was not validated in the Spanish cohort which may be due to variation in frequencies across 
populations, with the minor allele (A) being less common in Spanish individuals. This is further supported by in 
silico down-sampling of the UK cohort to similar numbers of cases and controls than the Spanish cohort reveal-
ing an association P-value for rs11913168 of 0.061 which is much more significant than the association in the 
Spanish cohort. Overall, the frequencies observed in our study were in line with those reported in dbSNP where 
the HapMap data showed 89.9% of the major allele G and 10.1% of the minor allele A while the 1000 Genome 
project reported 89.4% and 10.6% for allele G and A respectively in Europeans.
Concerning rs11913168, a potential gene regulated by this polymorphism could be the LIF gene located 
around 30 Kb downstream. In addition to our genomic data as well as chromatin interaction evidence, we found 
this gene to be up-regulated following microbial stimuli in epithelial cells. Similarly, an earlier report showed an 
increased LIF expression in rat trachea after treatment with LPS29. This suggests that LIF gene product plays a role 
in defense against pathogens. Indeed, LIF encodes a cytokine of the IL-6 superfamily, it has various functions, 
including signaling to immune cells such as T-cells and monocytes30 which is particularly important in the case of 
infection. Moreover, we showed that LIF looks to be regulated by the NF-kB pathway and we have data suggesting 
that RELA binding at rs11913168 would be influenced by the nucleotide present at this particular location. Taking 
this into account, we can hypothesize that the variation in RELA binding at the rs11913168 locus could influence 
the expression of the LIF gene downstream, leading to fluctuations in this cytokine’s secretion. This would in turn 
have consequences on the recruitment and communication with specialized immune cells needed to fight the 
pathogen (see Supplementary Fig. S9 for a schematic). However, differential RELA binding as well as its effect on 
LIF regulation warrant further experimental validation. Notably, the allelic bias observed in the ChIP-seq data 
in Detroit 562 cells should be further quantified. These cells consist of a cancer cell line and could contain more 
than two copies of each chromosome, therefore the bias observed may not reflect the actual binding preference 
of the transcription factor.
From previous GWAS performed on the same cohorts, several SNPs were identified as associated with menin-
gococcal susceptibility, they were located close to the CFH and CFHR3 genes15,16. Although two regions at the 
CFH locus were included in the custom capture used in this study, they did not overlap with the variants iden-
tified in the GWAS (Supplementary Fig. S10). As a result, the previously associated SNPs were not investigated 
in our study. Moreover, we observe that the RELA and H3K27ac ChIP-seq signal around these regions is low in 
both epithelial cell lines studied. This is consistent with the expression of CFH which is produced primarily by the 
liver31. Other variants have been associated with MD susceptibility13, however, a closer observation revealed that 
none of them overlapped the capture designed.
Conclusion
In this study, we employed a novel method to discover new regulatory polymorphisms driving genetic suscepti-
bility to MD. By using genomic data generated in a relevant cell type – nasopharyngeal epithelial cells – and under 
relevant stimulation – bacterial stimuli – we designed a capture for targeted sequencing of cohorts of MD patients 
and healthy controls. Following validation, we were able to identify two new putative regulatory variants that 
showed association with MD susceptibility.
Methods
Custom capture design. The capture used in this study was based on data generated previously in Detroit 
562 cells5,6, available in the NCBI’s Gene Expression Omnibus repository under the following accession number: 
(i) GSE91018 for RELA ChIP-seq data under microbial stimuli, (ii) GSE91019 for the RNA-seq data following 
microbial stimuli and (iii) GSE104635 for the H3K27ac ChIP-seq data under LPS stimulation. In addition, RELA 
ChIP-seq, RNA-seq and H3K27ac ChIP-seq data generated in the FaDu cells treated with LPS is available on 
demand.
Briefly, the regions selected to design the capture were the following: (i) RELA binding sites located within 
200 Kb of a differentially regulated genes following stimulation with bacterial stimuli (LPS, Pam2CSK4 or M 
tri-DAP) or TNFa in Detroit 562 cells, (ii) H3K27ac regions that showed a signal consistently higher under LPS 
stimulation compared to control, (iii) RELA binding sites within 200 Kb of differentially expressed genes under 
LPS treatment in FaDu cells and (iv) H3K27ac regions with a higher signal in LPS than Control ChIP-seq in FaDu 
cells. At the time of the capture design, some duplicates of these experiments were not available, thus some of the 
gene expression data was not replicated, as detailed in the results section for FBLN1.
The coordinates of the selected regions were submitted to Nimbelgen via their website for the design of the 
custom capture and the hybridization probes were then ordered.
Targeted sequencing. Genomic DNA libraries from 475 Western European samples (238 cases and 237 
controls) were prepared previously with the NEBNext Library Prep kit (New England Biolabs) according to the 
manufacturer’s instructions. After library building, each sample was loaded on a DNA 1000 chip and run on the 
Bioanalyzer (Agilent) for quality check and quantification. Based on this concentration, equal amounts (58.82 ng) 
of DNA from each of the 17 samples (either 8 controls and 9 cases or 9 controls and 8 cases) that made up a mul-
tiplexed capture reaction were pooled together, resulting in 1 µg of total DNA/Capture pool. Hybridization was 
then performed according to the SeqCap EZ system (Nimbelgen) protocol (SeqCap EZ Library SR User’s Guide 
v5.1) as follow. The pooled DNA was mixed with 5 µg of COT DNA, 1 nmol of universal oligo (MP-HE-1) and 1 
nmol of Terminator oligo pool matching our custom indexes. The mix was dried up in a desiccator at 60 °C for 20 
to 30 minutes and resuspended in 7.5 µl of 2X SC Hybridization Buffer and 3 µl of SC Hybridization component 
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A. DNA was denatured by incubating the tubes for 10 minutes at 95 °C before being transferred to a 4.5 µl aliquot 
of biotinylated custom capture and incubated at 47 °C for 50–52 hours. The samples were then washed according 
to the manufacturer’s instructions. Post-capture PCR was performed with the Phusion High Fidelity master mix 
(New England Biolabs). Briefly, 150 uL of the 2X master mix was added to the 50 µl of beads from the capture, 
together with 3 µl of each primers (MP_PE_POST 1 and 2) and 94 µl of water. Six aliquots of 50 µl were loaded 
into a PCR strip and the following program was applied: 1 min at 98 °C + 18 × (30 seconds at 98 °C + 30 seconds 
at 60 °C + 30 seconds at 72 °C) + 1 minutes at 72 °C. The samples were then purified with 0.9X Ampure beads and 
loaded on a DNA 1000 chip to be run on the Bioanalyzer for quality check and quantification. Hybridization reac-
tions were diluted to 10 nM and 2 reactions were pooled together in equal amount for sequencing on one lane. 
Libraries were sequenced on an Illumina Hi-seq (paired end 2 × 101 reads) lane. The sequences of the primers 
and oligos used can be found in Supplementary Table S7.
Hybridization quality control by qPCR. Selected hybridization reactions were tested by qPCR for 
enrichment of negative and positive loci as follows. Pooled genomic DNA libraries (Pool) as well as post-capture 
PCR products (Post Capture) were diluted to 5 ng/µl and 1 µl was used per reaction. Primers for 2 positive 
loci (NFKBIA and TNF) and 2 negative loci (ACTB and chr12D) were used, sequences can be found below. 
Quantitative PCR with LightCycler 480 SYBR Green I Master mix (Roche) was performed according to the man-
ufacturers’ instructions in triplicates. The following PCR program was used: 5 minutes at 95 °C; 45 × (10 seconds 
at 95 °C, 1 minutes at 65 °C, 30 seconds at 72 °C). The fold enrichment for each locus was calculated using the 
following formula: 2^(average Ct value of the Pool sample – average Ct value of the Post Capture sample).
Discovery phase: variant calling and association analysis. Sequencing reads were mapped to the tar-
geted regions of the human genome build hg19 using bwa32, followed by local realignment and base quality score 
recalibration of the reads. The following analyses were then performed with GATK 3.517. Depth of coverage as well 
as interval quality control were run on each sample with the modules DepthOfCoverage and DiagnoseTargets 
respectively. SNPs were called in all samples from the discovery cohort together using the Unified Genotyper 
module. To obtain high quality variants, SNPs with: (i) a quality score < 50, or (ii) QD < 2, or (iii) FS > 60, or 
(iv) MQ < 40, or (v) haplotype score > 13, or (vi) MQRankSum < −12.5, or (vii) ReadPosRankSum < −8 were 
further removed.
The rest of the analyses was performed in PLINK v1.0733. Mono-allelic SNPs were removed and further fil-
tering was performed: SNPs with (i) minor allele frequency (MAF) < 0.5%, or (ii) genotyping rate < 95%, or (iii) 
deviation from Hardy-Weinberg equilibrium in controls with a P-value < 0.0001, or (iv) significantly different 
genotyping rate between case and controls were removed (Supplementary Fig. S3).
Sample filtering was performed as follow: (i) samples with first degree relatives identified with identity by 
descent analysis were removed (keeping only the sample with the highest genotyping rate per pair), (ii) Principal 
Component Analysis (PCA) outliers were removed based on PCA1 and PCA2 (PCA analysis was performed 
using the GWAS data available to us, extracted for the 475 samples of the discovery cohort), and (iii) samples with 
a call rate < 95% were filtered out (Supplementary Fig. S3).
Association analysis was performed on the final set of variants (30,542 SNPs) between 235 case and 225 con-
trol samples remaining using a logistic regression model in PLINK (–logistic). In addition, the option–adjust was 
used to correct for population heterogeneity with the genomic inflation factor (GC). For this population, GC 
reported was 1.049 thus the P-values reported from the association were corrected with this factor (GC P-values).
Validation phase: SNP selection and mass array genotyping. Based on the results from the discov-
ery phase, SNPs were selected for validation if: (i) their association P-value < 0.005, (ii) they were not in linkage 
disequilibrium with other SNPs (r2 < 0.9), keeping one SNP per LD block, (iii) they were not present on the 
GWAS array used to type the validation cohorts, and (iv) their MAFs were not too divergent from databases or 
too low to be replicated (<4%). Finally, 42 SNPs were selected for validation and submitted to design a custom 
Sequenom Multiplex MassArray assay. One SNP failed to be designed so 41 SNPs were left and genotyped in three 
validation cohorts according to the manufacturer’s instructions.
Stringent thresholds of 95% call rate for SNPs and 95% genotyping rate for samples were applied to filter the 
data. Fourteen SNPs were filtered out at this step; 27 SNPs remained for the association analysis. The samples 
consisted of 3 cohorts containing the following number of samples: 501 in Western European (Dutch together 
with Austrian) cohort (350 cases and 332 controls), 1182 in the Spanish cohort (262 cases and 920 controls) and 
827 in the British cohort (639 cases and 189 controls). The three cohorts were first analyzed for association sep-
arately in PLINK v1.07. The same additional SNP filtering steps were applied: SNPs with (i) MAF < 0.5%, or (ii) 
genotyping rate < 95%, or (iii) deviation from Hardy-Weinberg equilibrium in controls with a P-value < 0.0001, 
or (iv) significantly different genotyping rate between case and controls were removed. Two SNPs were filtered 
out, so 25 SNPs were left for the association analysis. The same procedure was used to perform the association test 
with a logistic regression model and correcting for population heterogeneity. The GC reported were 1.478, 1.215 
and 1.000 for the Western European, British and Spanish cohort respectively.
Validation by GWAS array typing. As some of the SNPs called during the discovery phase were included 
in the GWAS array used on the same cohorts previously15, they were not included in the Sequenom assay and 
the data from the GWAS array (typed and imputed genotypes) was used instead. The selected SNPs with an 
association P-value in the discovery phase < 0.05 were extracted from the GWAS data in the Western European 
(excluding the samples present in the discovery cohort), Spanish and British cohorts. The following number of 
samples were available: 2541 in Western European cohort (147 cases and 2394 controls), 1332 in the Spanish 
cohort (422 cases and 910 controls) and 5178 in the British cohort (475 cases and 4703 controls). The same 
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SNP filtering in PLINK was done: SNPs with (i) MAF < 0.5%, or (ii) genotyping rate < 95%, or (iii) deviation 
from Hardy-Weinberg equilibrium in controls with a P-value < 0.0001, or (iv) significantly different genotyping 
rate between case and controls were removed. This resulted in 744 SNPs to analyze for association, the analysis 
was performed as mentioned above. The GC coefficients reported were 1.000, 1.100 and 1.113 for the Western 
Europe, UK and Spain cohorts respectively. Each validation cohort was analyzed separately and a meta-analysis 
together with the discovery cohort was performed. In order to further select the SNPs to follow up, we focused on 
those variants that were typed rather than imputed, present in all three validation cohorts, and with a discovery 
P-value < 0.01 which resulted in 9 SNPs remaining.
Meta-analysis. In order to combine and analyze the discovery together with the validation cohorts, 
a meta-analysis was performed using the PLINK function–meta-analysis and including the 4 cohorts 
(Discovery-Western Europe, Validation-Spain, Validation-UK and Validation-Western Europe). The value I 
given by the program was used as a measure of the heterogeneity between cohorts, thus when I was low (<5), 
the fixed-effects P-value and OR was used while when I was high (>5), the random effect P-value and OR was 
reported.
Evidences for significance. The following resources were used to further investigate the two SNPs reported 
in this study: db SNP: https://www.ncbi.nlm.nih.gov/projects/SNP/. Known alleles and frequencies for the SNPs 
in the European population were inquired in this data base using the SNP rs ID as search word. HaploReg (version 
4.1): http://archive.broadinstitute.org/mammals/haploreg/haploreg.php. Search was conducted using the SNPs rs 
ID. Regulome DB (version 1.1): http://www.regulomedb.org/index. The list of SNPs showing a meta-analysis 
P-value < 0.05 was submitted to the web interface and a score for each SNP was returned as well as information 
described in the text. HiView: http://www.unc.edu/~yunmli/HiView/. This website allows browsing of the data 
on chromatin interaction in IMR90 fibroblast cell line from Jin et al.22. Search was conducted using a SNP rs ID 
as input, returning the fragment of DNA containing the SNP as bait, highlighted in blue, and the interactions 
observed with the surrounding regions (Supplementary Fig. S8). Data bases of known NF-kB targets: http://bio-
info.lifl.fr/NF-KB/ and https://www.bu.edu/nf-kb/gene-resources/target-genes/. The two lists were browsed for 
LIF, to examine whether it is a known NF-kB target. UCSC genome browser: http://genome.ucsc.edu/. Our own 
genomic data (RELA and H3K27ac ChIP-seq) were loaded to examine the signal at each SNP location. In addi-
tion, the following public tracks were added: UCSC genes, ENCODE transcription factor binding sites, layered 
H3K27ac mark and PhyloP score.
Allelic bias. In order to investigate allelic bias, the genomic data generated in Detroit 562 and FaDu cells 
were used. For each cell line, the reads from all RELA ChIP-seq experiments performed previously were pooled 
and the subset of them located 2 Kb around the SNPs identified in our study were extracted using samtools view 
and samtools merge. The same was done for H3K27ac ChIP-seq in Control and LPS condition as well as Input 
DNA. Subsequently, the newly extracted bam files were sorted (samtools sort), duplicates were removed (sam-
tools rmdup) and they were indexed (samtools index) in order to be loaded onto the IGV software. Each SNP was 
then examined and considered for heterozygosity in both cell lines.
Rs11913168 was found to be heterozygous in Detroit 562 cells and the number of reads carrying the G and 
A alleles, mapping on each of the plus or minus DNA strand was extracted for each condition. Strand bias was 
investigated with a Fisher exact test using the 2 × 2 table calculator at http://vassarstats.net/index.html. The Fisher 
one-tailed P-value is reported for each data set in Supplementary Fig. S8B. Actual allelic bias was then evaluated 
with a Binomial test against the probability of each allele occurring in 50% of cases, using the binom.test com-
mand in R. P-values from this test are reported in Table 3.
Cell culture and treatment. FaDu cells were purchased from ATCC and cultured in RPMI medium 
(Gibco) supplemented with 10% fetal bovine serum performance (Gibco), 100 U/ml penicillin and 100 ug/ml 
streptomycin (Gibco), and 1 mM sodium pyruvate (Gibco). LPS from E. coli B4:111 (Sigma) at 1 μg/mL was used 
to stimulate the cells. Inhibition of NFKB was achieved using BAY 11–7082 (ChemCruz) at 50 uM (stock solu-
tion at 50 mM in DMSO) for one hour prior and at 45 uM (dilution 9/10 in the medium containing the ligand) 
during the treatment. RELA activation as well as gene expression were performed as described in Supplementary 
Table S7.
RELA activation assay. After treatment of the FaDu cells, the cytoplasmic and nuclear proteins were 
extracted using the NE-PER kit (Pierce) and quantified with the Coomasie Protein quantification kit (Pierce). 
Ten to 15 ug of nuclear proteins were used to test RELA activation using the NFκB p65 transcription factor assay 
kit (Pierce) according to the manufacturer’s instructions.
RT-qPCR. FaDu cells were treated with LPS or fresh medium for 80 minutes and total RNAs were extracted. 
One microgram of was used for reverse transcription using QuantiTect Reverse Transcription kit (Qiagen) fol-
lowed by qPCR with LightCycler 480 SYBR Green I Master (Roche) according to the manufacturers’ instructions. 
The following PCR program was used: 5 minutes at 95 °C; 45 × (10 seconds at 95 °C, 1 minutes at 65 °C, 30 seconds 
at 72 °C). The ΔΔCt method was applied to determine the fold change of the genes of interest under LPS com-
pared to the control, normalized with 2 housekeeping genes (ACTB, GAPDH). Sequences of the primers used for 
qPCR are shown below.
Use of human samples. All samples have been collected under the Ethikkomission of the Medizinische 
Universitat Graz (Reference Number 24–116 ex 11/12), methods were carried out in accordance with relevant 
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guidelines and regulations and all experimental protocols were approved by the same Review board. Informed 
consent was obtained from all subjects or, if subjects are under 18, from a parent and/or legal guardian.
Ethical approval and informed consent. All samples have been collected under country-specific 
Institutional Review Boards. The following review boards approved the protocols: St Mary’s Research 
Ethics Committee (EC3263) and Medical Ethics Committee Erasmus MC (MEC 154.304/1996/139, MEC 
190.703/2000/79 and MEC 217.867/2002/226).
A common clinical protocol agreed by the EUCLIDS Clinical Network and approved by all ethics committees 
was implemented at all hospitals. All clinical staff were trained in the project’s procedures and specified criteria 
were used for clinical definitions and assignment of patients to diagnostic categories. Written informed consent 
was obtained from a parent or legal guardian for each patient before inclusion in the study.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
References
 1. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating the dark road from association to function. 
American journal of human genetics 93, 779–797, https://doi.org/10.1016/j.ajhg.2013.10.012 (2013).
 2. Reddy, T. E. et al. Effects of sequence variation on differential allelic transcription factor occupancy and gene expression. Genome 
research 22, 860–869 (2012).
 3. Kilpinen, H. et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science 342, 
744–747 (2013).
 4. Albert, F. W. & Kruglyak, L. The role of regulatory variation in complex traits and disease. Nature reviews. Genetics 16, 197 (2015).
 5. Borghini, L., Lu, J., Hibberd, M. & Davila, S. Variation in Genome-Wide NF-kappaB RELA Binding Sites upon Microbial Stimuli 
and Identification of a Virus Response Profile. Journal of immunology (Baltimore, Md.: 1950), https://doi.org/10.4049/
jimmunol.1800246 (2018).
 6. Borghini, L., Hibberd, M. & Davila, S. Changes in H3K27ac following lipopolysaccharide stimulation of nasopharyngeal epithelial 
cells. BMC Genomics 19(1) (2018).
 7. Stephens, D. S., Greenwood, B. & Brandtzaeg, P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 
2196–2210, https://doi.org/10.1016/S0140-6736(07)61016-2 (2007).
 8. Caugant, D. A., Tzanakaki, G. & Kriz, P. Lessons from meningococcal carriage studies. FEMS microbiology reviews 31, 52–63 (2007).
 9. Mogensen, T. H., Paludan, S. R., Kilian, M. & Ostergaard, L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria 
meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 80, 
267–277 (2006).
 10. Girardin, S. E. et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. science 300, 1584–1587 
(2003).
 11. Hayden, M. S. & Ghosh, S. Signaling to NF-κB. Genes & development 18, 2195–2224 (2004).
 12. Haralambous, E. et al. Sibling familial risk ratio of meningococcal disease in UK Caucasians. Epidemiology and infection 130, 
413–418 (2003).
 13. Wright, V., Hibberd, M. & Levin, M. Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility 
and severity genes. Vaccine 27, B90–B102 (2009).
 14. Parker, D. & Prince, A. Innate immunity in the respiratory epithelium. American journal of respiratory cell and molecular biology 45, 
189–201, https://doi.org/10.1165/rcmb.2011-0011RT (2011).
 15. Davila, S. et al. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to 
meningococcal disease. Nature genetics 42, 772–776, https://doi.org/10.1038/ng.640 (2010).
 16. Martinón-Torres, F. et al. Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide 
association studies. Scientific reports 6, 35842 (2016).
 17. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature 
genetics 43, 491–498 (2011).
 18. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).
 19. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
 20. Uhlen, M. et al. Towards a knowledge-based human protein atlas. Nature biotechnology 28, 1248–1250 (2010).
 21. Calo, E. & Wysocka, J. Modification of enhancer chromatin: what, how, and why? Molecular cell 49, 825–837 (2013).
 22. Jin, F. et al. A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature 503, 290–294, https://
doi.org/10.1038/nature12644 (2013).
 23. Waragai, M. et al. Ataxin 10 induces neuritogenesis via interaction with G‐protein β2 subunit. Journal of neuroscience research 83, 
1170–1178 (2006).
 24. Tian, J. et al. Aurora B-dependent phosphorylation of Ataxin-10 promotes the interaction between Ataxin-10 and Plk1 in 
cytokinesis. Scientific reports 5 (2015).
 25. Warner, N. et al. A genome-wide siRNA screen reveals positive and negative regulators of the NOD2 and NF-κB signaling pathways. 
Science signaling 6 (2013).
 26. Warner, N., Burberry, A., Pliakas, M., McDonald, C. & Núñez, G. A genome-wide small interfering RNA (siRNA) screen reveals 
nuclear factor-κB (NF-κB)-independent regulators of NOD2-induced interleukin-8 (IL-8) secretion. Journal of Biological Chemistry 
289, 28213–28224 (2014).
 27. Attwooll, C., Denchi, E. L. & Helin, K. The E2F family: specific functions and overlapping interests. The EMBO journal 23, 
4709–4716 (2004).
 28. Lim, C. A. et al. Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB 
upon TLR4 activation. Molecular cell 27, 622–635, https://doi.org/10.1016/j.molcel.2007.06.038 (2007).
 29. Ulich, T. R. et al. Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. 
American Journal of Physiology-Lung Cellular and Molecular Physiology 267, L442–L446 (1994).
 30. Nicola, N. A. & Babon, J. J. Leukemia inhibitory factor (LIF). Cytokine & growth factor reviews 26, 533–544 (2015).
 31. Ferreira, V. P., Pangburn, M. K. & Cortés, C. Complement control protein factor H: the good, the bad, and the inadequate. Molecular 
immunology 47, 2187–2197 (2010).
 32. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
 33. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. The American Journal of 
Human Genetics 81, 559–575 (2007).
1 2Scientific RepoRts |          (2019) 9:6966  | https://doi.org/10.1038/s41598-019-43292-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
We thank Kumar Vikrant for his advices on the association analysis as well as Phua Zai Yang for his help on 
the library preparation and hybridization. The Next Generation Sequencing Platform and the Research Pipeline 
Development team at the Genome Institute of Singapore made the sequencing possible as well as data processing 
and mapping of the reads. In addition, we acknowledge A*STAR for the SINGA scholarship awarded to LB. 
Finally, we would like to thank all children and parents who participated in this study. S.D., E.P., M.H. and L.B. 
were supported by the Agency for Science Technology and Research of Singapore (A*STAR). This work has been 
partially funded by the European Seventh Framework Programme for Research and Technological Development 
(FP7) under EUCLIDS Grant Agreement No. 279185. The UK meningococcal cohort was established with 
support from Meningitis Research Foundation through grants to Imperial College London. The Research from 
Newcastle partners was supported by the National Institute for Health Research Newcastle Biomedical Research 
Centre based at Newcastle Hospitals NHS Foundation Trust and Newcastle University. The views expressed are 
those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The ESIGEM 
Research group activities were supported by grants from Instituto de Salud Carlos III (Proyecto de Investigación 
en Salud, Acción Estratégica en Salud: proyecto GePEM PI16/01478) (A.S.); Consellería de Sanidade, Xunta de 
Galicia (RHI07/2-intensificación actividad investigadora, PS09749 and 10PXIB918184PR), Instituto de Salud 
Carlos III (Intensificación de la actividad investigadora 2007–2016), Convenio de colaboración de investigación 
(Wyeth España-Fundación IDICHUS 2007–2011), Convenio de colaboración de investigación (Novartis España-
Fundación IDICHUS 2010–2011), Fondo de Investigación Sanitaria (FIS; PI070069/PI1000540) del plan nacional 
de I + D + I and ‘fondos FEDER’ (F.M.T.). The Swiss Pediatric Sepsis study was funded by grants from the Swiss 
National Science Foundation (342730_153158/1), the Swiss Society of Intensive Care, the Bangerter Foundation, 
the Vinetum and Borer Foundation, and the Foundation for the Health of Children and Adolescents. The 
Western Europe Meningococcal Study was supported by grants no 8842, 10112 and 12710 of the Oesterreichische 
Nationalbank (Austria), grants A3-16.K-8/2008-11 and A3-16.K-8/2006–9 of the Department for Science and 
Research of the Styrian federal government (Austria) and the non for profit association ‘In Vita’, Graz (Austria).
Author Contributions
S.D. designed the study, L.B. performed the experiments and the analyses with occasional help from E.P., M.H. 
provided support and comments of the results. A.B., V.W., R.dG., J.H., M.E., S.A., C.F., E.C., A.P., T.K., F.M.T., 
W.Z., M.L., M.H., S.D., E.P., M.V.dF., L.S., F.S., A.S. and L.C. obtained funding and designed the clinical study. All 
the EUCLIDS authors have contributed to patient recruitment and inclusion and clinical assessment. L.B. wrote 
the manuscript with the help of S.D.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-43292-6.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
13Scientific RepoRts |          (2019) 9:6966  | https://doi.org/10.1038/s41598-019-43292-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Consortia
EUCLIDS consortium
Stuart Gormley4, Shea Hamilton4, Jethro Herberg4, Bernardo Hourmat4, Clive Hoggart4, 
Myrsini Kaforou4, Vanessa Sancho-Shimizu4, Amina Abdulla4, Paul Agapow4, Maeve Bartlett4, 
Evangelos Bellos4, Hariklia Eleftherohorinou4, Rachel Galassini4, David Inwald4, Meg 
Mashbat4, Stefanie Menikou4, Sobia Mustafa4, Simon Nadel4, Rahmeen Rahman4, Clare 
Thakker4, S. Bokhandi25, Sue Power25, Heather Barham25, N. Pathan26, Jenna Ridout26, 
Deborah White26, Sarah Thurston26, S. Faust27, S. Patel27, Jenni McCorkell27, P. Davies28, 
Lindsey Cratev28, Helen Navarra28, Stephanie Carter28, R. Ramaiah29, Rekha Patel29, Catherine 
Tuffrey30, Andrew Gribbin30, Sharon McCready30, Mark Peters30, Katie Hardy30, Fran 
Standing30, Lauren O’Neill30, Eugenia Abelake30, Akash Deep31, Eniola Nsirim31, Louise 
Willis17, Zoe Young17, C. Royad32, Sonia White32, P. M. Fortune33, Phil Hudnott33, Fernando 
Álvez González20,21, Ruth Barral-Arca15,20,21, Miriam Cebey-López20,21, María José Curras-
Tuala15,20,21, Natalia García20,21, Luisa García Vicente20,21, Alberto Gómez-Carballa15,20,21, Jose 
Gómez Rial20,21, Andrea Grela Beiroa20,21, Antonio Justicia Grande20,21, Pilar Leboráns 
Iglesias20,21, Alba Elena Martínez Santos20,21, Nazareth Martinón-Torres20,21, José María 
Martinón Sánchez20,21, Belén Mosquera Pérez20,21, Pablo Obando Pacheco20,21, Jacobo Pardo-
Seco15,20,21, Sara Pischedda15,20,21, Irene Rivero Calle20,21, Carmen Rodríguez-Tenreiro20,21, 
Lorenzo Redondo-Collazo20,21, Sonia Serén Fernández20,21, María del Sol Porto Silva20,21, Ana 
Vega20,21,34, Susana Beatriz Reyes35, María Cruz León León35, Álvaro Navarro Mingorance35, 
Xavier Gabaldó Barrios35, Eider Oñate Vergara36, Andrés Concha Torre37, Ana Vivanco37, Reyes 
Fernández37, Francisco Giménez Sánchez38, Miguel Sánchez Forte38, Pablo Rojo39, J. Ruiz 
Contreras39, Alba Palacios39, Marisa Navarro40, Cristina Álvarez Álvarez40, María José 
Lozano40, Eduardo Carreras41, Sonia Brió Sanagustín41, Olaf Neth42, Ma del Carmen Martínez 
Padilla43, Luis Manuel Prieto Tato44, Sara Guillén44, Laura Fernández Silveira45, David 
Moreno46, A. M. Tutu van Furth47, M. van der Flier6, N. P. Boeddha7, G. J. A. Driessen7, D. 
Pajkrt19, E. A. M. Sanders48, D. van de Beek49, A. van der Ende49, H. L. A. Philipsen6, A. O. A. 
Adeel50, M. A. Breukels51, D. M. C. Brinkman52, C. C. M. M. de Korte53, E. de Vries54, W. J. de 
Waal55, R. Dekkers56, A. Dings-Lammertink57, R. A. Doedens58, A. E. Donker59, M. Dousma60, 
T. E. Faber61, G. P. J. M. Gerrits62, J. A. M. Gerver63, J. Heidema64, J. Homan-van der Veen65, M. 
A. M. Jacobs66, N. J. G. Jansen48, P. Kawczynski67, K. Klucovska68, M. C. J. Kneyber69, Y. 
Koopman-Keemink70, V. J. Langenhorst71, J. Leusink72, B. F. Loza73, I. T. Merth74, C. J. 
Miedema75, C. Neeleman6, J. G. Noordzij76, C. C. Obihara77, A. L. T. van Overbeek-van Gils78, G. 
H. Poortman79, S. T. Potgieter80, J. Potjewijd81, P. P. R. Rosias82, T. Sprong62, G. W. ten 
Tussher83, B. J. Thio84, G. A. Tramper-Stranders85, M. van Deuren6, H. van der Meer47, A. J. M. 
van Kuppevelt86, A. M. van Wermeskerken87, W. A. Verwijs88, T. F. W. Wolfs48, Philipp 
Agyeman13, Christoph Aebi13, Christoph Berger13,89, Eric Giannoni90,91, Martin Stocker92, Klara 
M Posfay-Barbe93, Ulrich Heininger94, Sara Bernhard-Stirnemann95, Anita Niederer-Loher96, 
Christian Kahlert96, Paul Hasters97, Christa Relly89, Walter Baer98, Stéphane Paulus99, Hannah 
Frederick99, Rebecca Jennings99, Joanne Johnston99, Rhian Kenwright99, Rachel Agbeko8,100, 
Kalifa Bojang14, Isatou Sarr14, Ngane Kebbeh14, Gibbi Sey14, Momodou Saidykhan14, 
Fatoumatta Cole14, Gilleh Thomas14, Martin Antonio14, Wolfgang Walcher101, Gotho 
Geishofer3, Daniela Klobassa3, Müller Martin3, Klaus Pfurtscheller3, Karl Reiter102, Siegfried 
Rödl3, Gerfried Zobel3, Bettina Zöhrer3, Bärbel Töpke103, Peter Fucik104, Markwart Gabriel105, 
Johann M. Penzien106, Gedeon Diab107, Robert Miething108, K. H. Deeg109, Jürg Hammer110, 
Ulrich Heininger111, Verena Varnholt112, Andreas Schmidt113, Lutz Bindl114, Ursula Sillaber115, 
Christian Huemer116, Primrose Meier117, G. Simic-Schleicher118, Markus Markart119, Eberhard 
Pfau120, Hans Broede121, Bernd Ausserer122, Hermann Kalhoff123, Volker Arpe124, Susanne 
Schweitzer-Krantz125, Johannes-Martin Kasper126, Kathrin Loranth127, Hans J. Bittrich128, 
Burkhard Simma129, Jens Klinge130, Michael Fedlmaier131, Nicola Weigand132, Egbert 
Herting133, Regina Grube134, Christoph Fusch135, Alois Gruber136, Ulf Schimmel137, Suzanne 
Knaufer-Schiefer138, Wolfgang Lässig139, Axel Hennenberger140, Axel von der Wense141, 
Roland Tillmann142, Jürgen Schwarick143, Friedrich C. Sitzmann144, Werner Streif145, Herbert 
Müller146, Peter Kurnik147, Peter Groneck148, Ute Weiss149, Helene Gröblacher-Roth150, Jürgen 
Bensch151, Reinhard Moser152, Rudolf Schwarz153, Kurt Lenz154, Thomas Hofmann155, 
Wolfgang Göpel156, Dietrich Schulz157, Thomas Berger158, Erwin Hauser159, Kai Martin 
Förster160, Jochen Peters161, T homas Nicolai162, Björn Kumlien163, Regina Beckmann164, 
1 4Scientific RepoRts |          (2019) 9:6966  | https://doi.org/10.1038/s41598-019-43292-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Christiane Seitz165, D. Hüseman166, Roland Schürmann167, Van Hop Ta168, Eckart Weikmann169, 
W. Evert170, Jürgen Hautz171, Jürgen Seidenberg172, Lucia Wocko173, Petra Luigs174, Hans-
Ludwig Reiter175, J. Quietzach176, Michael König177, Johanna Herrmann178, Horst Mitter179, 
Ekkehard Seidler180, Bernhard Maak181, Wolfgang Sperl182, Karl Zwiauer183, Manfred Meissl184, 
Reinhard Koch185, Manfred Cremer186, H. A. Breuer187, W. Görke188, Robert Nossal189, Walter 
Pernice190, Ralf Brangenberg191, Hans R. Salzer192, Hartmut Koch193, Gerhard Schaller194, 
Franz Paky195, Friedrich Straßer196, Franz Eitelberger197, D. Sontheimer198, Andreas 
Lischka199, Martina Kronberger200, Alfred Dilch201, Christian Scheibenpflug202, Robert 
Bruckner203, Klaus Mahler204, Klaus Runge205, Wolfgang Kunze206 & Peter Schermann207
25Poole Hospital nHS foundation trust, Poole, United Kingdom. 26cambridge University Hospitals nHS trust, 
cambridge, United Kingdom. 27University Hospital Southampton, Southampton, United Kingdom. 28nottingham 
University Hospital nHS trust, nottingham, United Kingdom. 29University Hospitals of Leicester nHS trust, 
Leicester, United Kingdom. 30Portsmouth Hospitals nHS trust, London, United Kingdom. 31King’s College Hospital 
nHS foundation trust, London, United Kingdom. 32Kettering General Hospital nHS foundation trust, Kettering, 
United Kingdom. 33central Manchester nHS trust, Manchester, United Kingdom. 34fundación Pública Galega de 
Medicina Xenómica, Servizo Galego de Saúde (SeRGAS), instituto de investigaciones Sanitarias (iDiS), and Grupo de 
Medicina Xenómica, centro de investigación Biomédica en Red de enfermedades Raras (ciBeReR), Universidade de 
Santiago de compostela (USc), Santiago de compostela, Spain. 35Hospital clínico Universitario Virgen de la Arrixaca, 
Murcia, Spain. 36Hospital de Donostia, San Sebastián, Spain. 37Hospital Universitario central de Asturias, Asturias, 
Spain. 38complejo Hospitalario torrecárdenas, Almería, Spain. 39Hospital Universitario 12 de Octubre, Madrid, Spain. 
40Hospital General Universitario Gregorio Marañón, Madrid, Spain. 41Hospital de la Santa creu i Sant Pau, Barcelona, 
Spain. 42Hospital Universitario Virgen del Rocío, Sevilla, Spain. 43complejo Hospitalario de Jaén, Jaén, Spain. 
44Hospital Universitario de Getafe, Madrid, Spain. 45Hospital Universitario y Politécnico de La fe, Valencia, Spain. 
46Hospital Regional Universitario carlos Haya, Málaga, Spain. 47Vrije Universiteit University Medical center, 
Amsterdam, the netherlands. 48University Medical Center Utrecht – Wilhelmina Children’s Hospital, Utrecht, The 
netherlands. 49Academic Medical center, University of Amsterdam, Amsterdam, the netherlands. 50Kennemer 
Gasthuis, Haarlem, the netherlands. 51elkerliek Hospital, Helmond, the netherlands. 52Alrijne Hospital, Leiderdorp, 
the netherlands. 53Beatrix Hospital, Gorinchem, the netherlands. 54Jeroen Bosch Hospital, ‘s-Hertogenbosch, The 
netherlands. 55Diakonessenhuis, Utrecht, the netherlands. 56Maasziekenhuis Pantein, Boxmeer, the netherlands. 
57Gelre Hospitals, Zutphen, the netherlands. 58Martini Hospital, Groningen, the netherlands. 59Maxima Medical 
center, Veldhoven, the netherlands. 60Gemini Hospital, Den Helder, the netherlands. 61Medical center Leeuwarden, 
Leeuwarden, the netherlands. 62Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. 63Rode Kruis Hospital, 
Beverwijk, the netherlands. 64St. Antonius Hospital, nieuwegein, the netherlands. 65Deventer Hospital, Deventer, 
the netherlands. 66Slingeland Hospital, Doetinchem, the netherlands. 67Refaja Hospital, Stadskanaal, the 
netherlands. 68Bethesda Hospital, Hoogeveen, the netherlands. 69University Medical center Groningen, Beatrix 
Children’s hospital, Groningen, The Netherlands. 70Haga Hospital – Juliana Children’s Hospital, Den Haag, The 
netherlands. 71isala Hospital, Zwolle, the netherlands. 72Bernhoven Hospital, Uden, the netherlands. 73Viecuri 
Medical center, Venlo, the netherlands. 74Ziekenhuisgroep Twente, Almelo-Hengelo, The Netherlands. 75catharina 
Hospital, eindhoven, the netherlands. 76Reinier de Graaf Gasthuis, Delft, the netherlands. 77etZ elisabeth, tilburg, 
the netherlands. 78Scheper Hospital, emmen, the netherlands. 79St. Jansdal Hospital, Hardewijk, the netherlands. 
80Laurentius Hospital, Roermond, the netherlands. 81isala Diaconessenhuis, Meppel, the netherlands. 82Zuyderland 
Medical Center, Sittard-Geleen, The Netherlands. 83Westfriesgasthuis, Hoorn, the netherlands. 84Medisch Spectrum 
twente, enschede, the netherlands. 85St. franciscus Gasthuis, Rotterdam, the netherlands. 86Streekziekenhuis 
Koningin Beatrix, Winterswijk, the netherlands. 87flevo Hospital, Almere, the netherlands. 88Zuwe Hofpoort 
Hospital, Woerden, the netherlands. 89Division of Infectious Diseases and Hospital Epidemiology, and Children’s 
Research Center, University Children’s Hospital Zurich, Zurich, Switzerland. 90Service of neonatology, Lausanne 
University Hospital, Lausanne, Switzerland. 91infectious Diseases Service, Lausanne University Hospital, Lausanne, 
Switzerland. 92Department of Pediatrics, Children’s Hospital Lucerne, Lucerne, Switzerland. 93Pediatric infectious 
Diseases Unit, Children’s Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland. 94infectious 
Diseases and Vaccinology, University of Basel Children’s Hospital, Basel, Switzerland. 95Children’s Hospital Aarau, 
Aarau, Switzerland. 96Division of Infectious Diseases and Hospital Epidemiology, Children’s Hospital of Eastern 
Switzerland St. Gallen, St. Gallen, Switzerland. 97Department of neonatology, University Hospital Zurich, Zurich, 
Switzerland. 98Children’s Hospital Chur, Chur, Switzerland. 99Alder Hey Children’s Hospital, Department of Infectious 
Diseases, eaton Road, Liverpool, United Kingdom. 100Paediatric intensive care Unit, newcastle upon tyne Hospitals 
Foundation Trust, Great North Children’s Hospital, Newcastle upon Tyne, United Kingdom. 101Department of 
Obstetics and Gynecology, Medical University of Graz, Graz, Austria. 102Kinderklinik der LMU München am Dr. von 
Haunerschen Kinderspital, Munich, Germany. 103Ostalb-Klinikum, Aalen, Germany. 104Krankenhaus Amstetten, 
Amstetten, Austria. 105Klinikum Aschaffenburg, Aschaffenburg, Germany. 106Zentralklinikum Kinderkliniken, 
Augsburg, Germany. 107Kreiskrankenhaus Bad Hersfeld, Bad Hersfeld, Germany. 108Diakonie-Krankenhaus, Bad 
Kreuznach, Germany. 109Klinikum Bamberg, Bamberg, Germany. 110Universitäts-Kinderspital beider Basel, 
Pädiatrische intensivmedizin, Basel, Switzerland. 111Universitäts-Kinderspital beider Basel, Abt für Infektiologie, 
Basel, Switzerland. 112Uni-Klinikum Charité, Campus Virchow Klinikum, Berlin, Germany. 113St.-Agnes-Hospital, 
Bocholt, Germany. 114Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany. 115Landeskrankenhaus Bregenz, 
Abt für innere Medizin, Bregenz, Austria. 116Landeskrankenhaus Bregenz, Abt für Kinderheilkunde, Bregenz, Austria. 
117Zentralkrankenhaus Links d. Weser, Bremen, Germany. 118Zentralkrankenhaus Bremen-Nord, Bremen, Germany. 
119Ospedale di Bressanone, Brixen, italy. 120DRK-Krankenhaus Chemnitz-Rabenstein, Chemnitz, Germany. 
1 5Scientific RepoRts |          (2019) 9:6966  | https://doi.org/10.1038/s41598-019-43292-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
121Klinikum Lippe-Detmold GmbH, Detmold, Germany. 122Krankenhaus Dornbirn, Dornbirn, Austria. 123Städt. 
Kliniken Dortmund, Dortmund, Germany. 124St. Marien-Hospital Düren-Birkesdorf, Düren, Germany. 
125evangelisches Krankenhaus, Düsseldorf, Germany. 126St. Georg Klinikum eisenach gGmbH, eisenach, Germany. 
127Krankenhaus der Barmherzigen Brüder, eisenstadt, Austria. 128Helios Klinikum erfurt, erfurt, Germany. 
129Landeskrankenhaus feldkirch, feldkirch, Austria. 130Klinikum fürth, fürth, Germany. 131Klinikum Garmisch-
Partenkirchen, Garmisch-Partenkirchen, Germany. 132Klinikum Justus-Liebig-Uni-O, Gießen, Germany. 133Georg-
August Universitäts-Kinderklinik, Göttingen, Germany. 134University Klinik für neurologie, Graz, Austria. 135Klinikum 
d. Ernst-Moritz-Arndt-Universität, Greifswald, Germany. 136Krankenhaus der Schulschwestern Grieskirchen, 
Grieskirchen, Germany. 137Allg. Krankenhaus Hagen GmbH, Hagen, Germany. 138Ohrekreis-Klinikum, Haldensleben, 
Germany. 139Städt. Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, Germany. 140Kinderkrankenhaus 
Wilhelmstift, Hamburg, Germany. 141Altonaer Kinderkrankenhaus, Hamburg, Germany. 142Klinikum Kreis Herford, 
Herford, Germany. 143Kreiskrankenhaus Herzberg, Herzberg, Germany. 144University Klinik für Kinder- und 
Jugendmedizin, Homburg/Saar, Germany. 145University Klinik für Kinder- und Jugendheilkunde Innsbruck, Innsbruck, 
Austria. 146Klinik Robert-Weixler-Strasse, Kempten, Germany. 147Landeskrankenhaus Klagenfurt, Klagenfurt, Austria. 
148Kinderklinik der Stadt Köln, Köln, Germany. 149Achenbach-Kreiskrankenhaus, Königs Wusterhausen, Germany. 
150Landeskrankenhaus Krems a. d. Donau, Krems a.d. Donau, Austria. 151Vinzentius-Krankenhaus, Landau, Germany. 
152Landeskrankenhaus Leoben, Leoben, Austria. 153Landes-Kinderklinik Linz, Linz, Austria. 154Konventhospital der 
Barmherzigen Brüder, Linz, Austria. 155evangelisches Krankenhaus, Lippstadt, Germany. 156Med. Universität zu 
Lübeck, Lübeck, Germany. 157Städtisches Klinikum Lüneburg, Lüneburg, Germany. 158Kantonspital Luzern, Luzern, 
Switzerland. 159Landeskrankenhaus Mödling, Mödling, Austria. 160Städt. Krankenhaus Harlaching, München, 
Germany. 161Kinderklinik der tU München, München, Germany. 162Kinderklinik im Dr. v. Haunerschen Kinderspital, 
München, Germany. 163Kinderklinik des Dritten Ordens, München, Germany. 164Dietrich-Bonhoeffer-Klinikum, 
neubrandenburg, Germany. 165FEK-Friedrich-Ebert-Krankenhaus. Neumünster GmbH, Neumünster, Germany. 
166Ruppiner Kliniken GmbH, neuruppin, Germany. 167Städt. Kliniken neuss Lukaskrankenhaus GmbH, neuss, 
Germany. 168evangelisches Krankenhaus, Oberhausen, Germany. 169Landeskrankenhaus Oberwart, Oberwart, 
Austria. 170Städt. Kliniken Offenbach, Offenbach, Germany. 171Klinikum Offenburg, Offenburg, Germany. 
172Elisabeth-Kinderkrankenhaus, Oldenburg, Germany. 173Krankenhaus Oranienburg, Oranienburg, Germany. 174St.
Vincenz-Krankenhaus Frauen- u. Kinderklinik, Paderborn, Germany. 175Klinik für Kinder und Jugendliche am 
Städtischen Klinikum, Pforzheim, Germany. 176Vogtland-Klinikum Plauen GmbH, Plauen, Germany. 
177Oberschwaben Klinik gGmbH, Ravensburg, Germany. 178Kreiskrankenhaus Rendsburg, Rendsburg, Germany. 
179Krankenhaus der Barmherzigen Schwestern Ried, Ried i. innkreis, Austria. 180Kreiskrankenhaus Obergöltzsch-
Rodewisch, Rodewisch, Germany. 181Thüringen-Klinik “Georgius Agricola” gGmbH, Saalfeld, Germany. 
182Landeskrankenanstalten Salzburg, Salzburg, Austria. 183Landesklinikum Sankt Pölten, Sankt Pölten, Austria. 
184Landeskrankenhaus Schärding, Schärding, Austria. 185Leopoldina-Krankenhaus, Schweinfurt, Germany. 186DRK-
Kinderklinik Siegen, Siegen, Germany. 187Städt. Klinikum Solingen, Solingen, Germany. 188Johanniter Kinderklinik, 
Stendal, Germany. 189Olga Hospital Stuttgart, Stuttgart, Germany. 190Kreiskrankenhaus torgau, torgau, Germany. 
191Klinikum traunstein, traunstein, Germany. 192Landeskrankenhaus tulln, tulln, Austria. 193St. Marien-Hospital, 
Vechta, Germany. 194Landeskrankenhaus Villach, Villach, Austria. 195Landeskrankenhaus Vöcklabruck, Vöcklabruck, 
Austria. 196Klinikum Weiden, Weiden, Germany. 197Krankenhaus der Barmherzigen Schwestern v. heiligen Kreuz, 
Wels, Austria. 198Harz-Klinikum Wernigerode GmbH, Wernigerode, Germany. 199Wilhelminenspital Wien, Wien, 
Austria. 200St. Anna Kinderspital, Wien, Austria. 201Gottfried von Preyersches Kinderspital der Stadt Wien, Wien, 
Austria. 202Donauspital im SMZ-Ost der Stadt Wien, Wien, Austria. 203Krankenhaus Wiener neustadt, Wiener 
neustadt, Austria. 204St. elisabeth Krankenhaus, Wittlich, Germany. 205Zentrum für Kinder- und Jugendmedizin, 
Wuppertal, Germany. 206Krankenhaus Muldentalkreis Wurzen, Wurzen, Germany. 207Krankenhaus Zwettl, Zwettl, 
Austria. 
